Treatment of ranula in pediatric patients with intralesional injection of OK-432.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 16735909.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To assess the efficacy of treatment of a ranula in children by intralesional injection of OK-432. Retrospective analysis of 13 cases. Review of medical records of pediatric patients with ranula treated by OK-432 sclerotherapy from 2002 through 2005. Among 13 cases, 9 were completely regressed by injection therapy alone. Three cases were incompletely regressed. One case was cured by surgical excision. The follow-up duration was 6 to 46 (mean 24.3) months. Adverse effects of OK-432 injection were tolerable, and no complication was observed. On the basis of our experience, sclerotherapy with OK-432 was a safe and effective primary treatment for a ranula in children. Further study will be needed to conclude its long-term effectiveness.
Medical subject headings
- Picibanil
- Ranula
- Sclerosing Solutions